8-K: Neuronetics Reports Strong Q1 2025 Revenue Growth Driven by Greenbrook Acquisition

Neuronetics' first quarter 2025 revenue surged 84% year-over-year to $32.0 million, primarily due to the acquisition of Greenbrook.

Summary

• Neuronetics, Inc. announced its Q1 2025 financial results, reporting total revenues of $32.0 million, an 84% increase compared to Q1 2024.
• The revenue growth was primarily driven by the acquisition of Greenbrook, which contributed $18.7 million in U.S. clinic revenue.
• U.S. treatment session revenue was $9.6 million, while U.S. NeuroStar Advanced Therapy System revenue reached $2.8 million.
• The company completed a secondary offering in February 2025, raising approximately $18.9 million in net proceeds.
• Gross margin for Q1 2025 was 49.2%, down from 75.1% in Q1 2024, due to the inclusion of Greenbrook's clinic business.
• Operating expenses increased by 35% to $26.8 million, mainly due to Greenbrook's general and administrative expenses.
• Net loss for Q1 2025 was $(12.7) million, or $(0.21) per share, compared to $(7.9) million, or $(0.27) per share, in Q1 2024.
• Cash and cash equivalents stood at $20.2 million as of March 31, 2025.
• The company expects Q2 2025 total worldwide revenue to be between $36.0 million and $38.0 million.
• Full-year 2025 total worldwide revenue is now expected to be between $149.0 million and $155.0 million, with a gross margin of approximately 55%.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While revenue growth is strong, the increased net loss and decreased gross margin raise concerns. The company's projection to be cash flow positive in Q3 2025 is a positive sign, but it remains a forward-looking statement.

Positives

• Significant revenue growth driven by the Greenbrook acquisition.
• Expansion of insurance coverage for adolescent TMS treatment.
• Successful completion of a secondary offering, strengthening the balance sheet.
• Projected cash flow positive in the third quarter of 2025.
• Increased average selling price per NeuroStar system by 9%.

Negatives

• Decrease in gross margin from 75.1% to 49.2% due to the inclusion of Greenbrook's clinic business.
• Increased operating expenses due to Greenbrook's general and administrative expenses.
• Net loss of $(12.7) million, although net loss per share improved from $(0.27) to $(0.21).
• U.S. NeuroStar Advanced Therapy System revenue decreased by 14% compared to Q1 2024.
• U.S. treatment session revenue decreased by 26% compared to Q1 2024.

Risks

• The company's ability to achieve or sustain profitable operations due to its history of losses.
• Reliance on the sale and usage of the NeuroStar Advanced Therapy System to generate revenues.
• Availability of coverage and reimbursement from third-party payors for treatments using the company's products.
• Developments in respect of competing technologies and therapies.
• The terms of the company's credit facility.
• The company's ability to successfully roll out the Better Me Provider Program on the planned timeline.
• The company's self-sustainability and existing cash balances.
• The company's ability to achieve cash flow breakeven in the third quarter of 2025.

Future Outlook

The company expects Q2 2025 total worldwide revenue to be between $36.0 million and $38.0 million, and full-year 2025 total worldwide revenue to be between $149.0 million and $155.0 million, with a gross margin of approximately 55%.

Management Comments

• Keith J. Sullivan, President and Chief Executive Officer of Neuronetics, stated that 2025 is off to a great start as their approach to innovative mental health treatment is improving access to care for patients and delivering value for providers.
• Sullivan also noted that growth initiatives for the Greenbrook clinics continue to exceed expectations, and the Better Me Provider program continues to prove its effectiveness.

Industry Context

The announcement reflects the growing trend of consolidation in the mental health services industry, with Neuronetics' acquisition of Greenbrook representing a move towards vertically integrated care models. The expansion of insurance coverage for adolescent TMS therapy also highlights the increasing recognition of TMS as a viable treatment option for depression.

Comparison to Industry Standards

• Given the limited information, a detailed comparison to industry standards is challenging.
• However, companies like LivaNova (LIVN), which also operates in the neuromodulation space, could be considered for benchmarking revenue growth and profitability.
• Acadia Healthcare (ACHC) and Universal Health Services (UHS) are examples of large behavioral health providers that could be compared to Greenbrook's clinic operations.
• Specific metrics such as revenue per clinic, treatment session volume, and reimbursement rates would be needed for a more granular comparison.

Management Changes

Stakeholder Impact

• Shareholders: Strengthened balance sheet and potential for future profitability.
• Employees: Integration of Greenbrook and potential changes in management.
• Patients: Increased access to mental health treatments through expanded coverage and clinic network.
• Providers: Improved value through the Better Me Provider program and expanded treatment options.

Next Steps

• Continue integration of Greenbrook and implementation of the Better Me Provider program.
• Expand the Spravato buy-and-bill model across the network of locations.
• Focus on achieving positive cash flow in the third quarter of 2025.
• Identify and hire a successor for the retiring Chief Financial Officer.

Key Dates

Keywords

Neuronetics, Greenbrook, TMS, NeuroStar, revenue, acquisition, therapy, treatment, depression, financial results